Navigation Links
Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
Date:7/31/2008

LOS ANGELES, July 31 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceuticals Corp. "Raptor's drug candidates, which target billion dollar markets, are progressing through the clinic at a rapid pace. The Company will present Phase 2 results for Convivia(TM) sometime in the 3rd quarter of 2008 and we expect FDA approval of Delayed Release (DR) Cysteamine for the treatment of cystinosis in 2010," stated Ross Silver, Director of Research for Vista Partners. For more information and to download the report for free, please visit the Vista Partners website at http://www.vistap.com and click on the "download research" icon.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About Raptor:

Raptor Pharmaceuticals Corp. ("Raptor") is a development-stage biopharmaceutical company leveraging novel drug-targeting platforms and reformulated therapeutics to improve treatment outcomes among patients with liver disorders, infectious diseases, cancer, and various orphan indications. The Company's clinical division advances internally developed and in-licensed clinical-stage product candidates towards marketing approval and commercialization and is currently involved in clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency as part of Raptor's Convivia(TM) program and nephropathic cystinosis as part of Raptor's DR Cysteamine program. Raptor's preclinical division
'/>"/>

SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
3. Synvista Therapeutics to Present at the BIO InvestorForum 2007
4. Synvista Therapeutics to be Featured on Wallst.net
5. Provista Awards Agreement to Spheris
6. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
9. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
10. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
11. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... WA (PRWEB) July 29, 2014 ... IRB services, has been awarded accreditation by the ... for its Lean Six Sigma Deployment Program. ... waste and improve performance. , Quorum’s Lean Six ... the Accredited Deployment Program designation. The designation is ...
(Date:7/29/2014)... The prestigious "Discovery or Exploration in History Award" ... Juliana Hillis and Kaylie O’Connell, students at Stoneham High ... Egg, Everything: America’s First IVF Baby". This project was ... History Day program during a week-long final competition judged ... D.C. , The growing popularity of the assisted reproductive ...
(Date:7/28/2014)... A new method of building materials using light, developed ... day enable technologies that are often considered the realm ... devices. , Although cloaked starships won,t be a ... have developed for constructing materials with building blocks a ... to control the way that light flies through them, ...
(Date:7/28/2014)... MD (PRWEB) July 28, 2014 ... personalized medicine, will be exhibiting data and research conducted ... International Spine Intervention Society’s (ISIS) 22nd Annual ... 3rd, at the Hyatt Regency, in Orlando, Florida. ... knowledge and clinical competence of physicians who care for ...
Breaking Biology Technology:Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3Building 'invisible' materials with light 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2
... Rich Schifreen, vice president of research products at Mirus-Bio ... operate in different fields of biotechnology. Platypus ... moving toward commercializing a new liquid crystal technology. ... , ,Schifreen joined Mirus in 2005. Before that, he ...
... Wis. Sonic Foundry, Inc. , said ... for the Blackboard Learning System , a course ... government institutions. , ,With the Mediasite "building block," a ... meeting in their web browser. Mediasite synchronizes video with ...
... said they work together so well because they know they ... The president and CEO of Alliant Energy said ... must be "joined at the hip" if information technology is ... a keynote address Thursday at the Fusion 2006 CEO-CIO ...
Cached Biology Technology:CEOs and CIOs must be 'joined at the hip' 2CEOs and CIOs must be 'joined at the hip' 3
(Date:7/27/2014)... to date, researchers from the U.K. provide national, regional, ... virus (HCV). Findings published in Hepatology, a journal of ... indicate that genotype 1 is the most prevalent worldwide, ... reside in East Asia. Genotype 3, at just over ... by genotypes 2, 4, 6, and 5. , ...
(Date:7/27/2014)... CANCER RESEARCH UK scientists at Barts Cancer Institute have ... make cancer therapy significantly more effective, according to research ... at Barts Cancer Institute, part of Queen Mary University ... adhesion kinase (FAK), signals the body to repair itself ... damaging DNA. When the researchers removed FAK from blood ...
(Date:7/25/2014)... colonial era, 100,000s of people lived on the land ... fire to control the availability of plants they used ... to use fire to maintain desired habitat and natural ... Forest Service,s Pacific Southwest Station, will lead a ... Refuge during the Ecological Society of America,s 99th Annual ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2New drug target can break down cancer's barrier against treatment 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... U.S. Department of Applied Neurobiology at the Walter Reed ... (AVC) have signed a Cooperative Research and Development Agreement ... brain injury (TBI). The alliance is based on ... NoNO Inc., of Toronto, Canada, and will explore the ...
... hospital superbugs can make poisons similar to those found ... scientists heard today (Monday 8 September 2008) at the ... week at Trinity College, Dublin. The toxins are ... called biofilms, which are up to a thousand times ...
... arsenic pollution have discovered a living sensor that can ... can clean up arsenic spills even in previously untreatable ... at the Society for General Microbiology,s Autumn meeting being ... Giant Mine in Canada is in the sub-arctic. It ...
Cached Biology News:Arbor Vita and WRAIR sign CRADA for traumatic brain injury collaboration 2Rattlesnake-type poisons used by superbug bacteria to beat our defenses 2Rattlesnake-type poisons used by superbug bacteria to beat our defenses 3Living sensor can warn of arsenic pollution 2
PEG 8000, Molecular Biology Grade...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Request Info...
Mouse Limitin MAb (Clone 183727)...
Biology Products: